There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
AZD3293 is a novel BACE1 inhibitor in Phase III development for Alzheimer's disease.
Sensitive and robust bioanalytical methods were required to quantitate AZD3293 and
its metabolite AZ13569724 in human biological matrices.